Beta-lactam and Beta-lactamase Inhibitors Market Analysis

Plastic Optic Fiber Market Report Thumbnail

Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), by Disease (Urinary Tract Infection (excluding cUTI), Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other), by Route of Administration (Oral, Intravenous, and others) - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Download PDF

Speak to Our Analyst

Download PDF

Speak to Our Analyst

Market Definition:

At an estimated value of over 27.49 billion USD in 2019, the global Beta-lactam and Beta-lactamase market is predicted to thrive at a CAGR of 1.9% and valued at over USD 34.20 billion over the forecast year 2020-2030.

Beta-lactam inhibitors fall under a class of antibiotics that consists of all antibiotic agents that have a beta lactam ring embedded in their molecular structure. These antibiotic agents helps fight against bacterial infections and protozoa infections. The antibiotic agent either completely kills the bacteria or prevents it from growing and expanding. Names of some beta-lactam antibiotics are penicillin, cephalosporin and many others. On the other hand, beta-lactamase inhibitors are a class of drugs that block the activity of beta-lactamase enzymes and restricts the degradation of beta-lactam. Beta-lactamase enzymes are created either constitutively or on exposure to antimicrobials.

Market Dynamics and Trends:

The widespread presence of infectious diseases along with the growth in consumption of identical drugs in developing countries indicate the growth of beta-lactam and beta-lactamase inhibitors market. Recent improvements in the healthcare sector and advancement of medical technology have further contributed to this market growth. The surge in number of clinical trials of such drugs have further augmented the growth of the market. However, evolution of antibiotic resistance and misuse due to over the counter availability are expected to impede the growth of beta-lactam and beta-lactamase Inhibitors market. Contradictorily, discovery of advanced prospect molecules and novel combination therapies are anticipated to offer significant opportunities to the market players and hence increase their beta-lactam and beta-lactamase inhibitors market share.

Market Segmentations and Scope of the Study:

The global beta-lactam and beta-lactamase inhibitors market share has been segmented on the basis of drug class, disease, route of administration and geography. On the basis of drug class, the market is categorized into Penicillin, Cephalosporin, Carbapanem, Monobactam and combination. Combination is sub segmented into Penicillin/Beta Lactamase inhibitors, Cephalosprin/Beta Lactamase inhibitors and Carbapanem/Beta inhibitors. On the basis of disease, the market is segmented into Urinary Tract Infection (excluding cUTI), Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection and others. Nosocomial Pneumonia is sub segmented into Hospital Acquired Pneumonia, Ventilator Associated Pneumonia and other. Based on route of administration, the market is segmented into oral, intravenous and others. In terms of geography, the market is categorized into North America, Europe, Asia Pacific and RoW.

Geographical Analysis:

The North America region is anticipated to hold the major market share as a result of advanced health care facilities and infrastructure in conjunction with rise in acceptance of beta-lactam and beta-lactamase inhibitors.

The Asia Pacific region is predicted to show rapid and consistent growth in market share within the forecast period. This region also indicates increased prevalence of infectious diseases in addition to rise in consumption of such drugs, which also serves as favorable factor for the beta-lactam and beta-lactamase inhibitor market.

Competitive Landscape:

Lucrative growth opportunities makes the Beta-lactam and Beta-lactamase inhibitors market extremely competitive. Some of the major players in the market include Abbott Laboratories, Allergan plc. F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck & Co. Inc. Mylan N.V., Novartis International AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries and more. A number of developmental strategies have been adopted by companies in the recent years to further promote the growth of the market. For instance, in 2019 Cipla gained rights to novel and patented its anti-infective called Elores. Also, In July 2019, imipenem-cilastatin-relebactam was also approved by the FDA for treating cUTIs and cIAIs.

KEY BENEFITS:

The Beta-lactam and Beta-lactamase Inhibitor market report provides the quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on
The study comprises a deep dive analysis of the Beta-lactam and Beta-lactamase Inhibitor market trend including the current and future trends for depicting the prevalent investment pockets in the market
The information related to key drivers, restraints and opportunities and their impact on the Beta-lactam and Beta-Lactamase Inhibitor market is provided in the report.
The market share of the players in the global Beta-lactam and Beta-lactamase Inhibitor market along with their competitive analysis.
Value chain analysis in the market study provides a clear picture of the stakeholders’ roles

KEY MARKET SEGMENTS:

By Drug Class

Penicillin
Cephalosporin
Carbapenem
Monobactam
Combination
- Penicillin/Beta Lactamase Inhibitor
- Cephalosporin/Beta Lactamase Inhibitor
- Carpabenem/Beta Lactamase Inhibitor

By Disease

Urinary Tract Infection
Respiratory Infection
Skin Infection
Complicated Urinary Tract Infection
Complicated Intra-Abdominal Infection
Nosocomial Pneumonia
- Hospital Acquired Pneumonia
- Ventilator Associated Pneumonia
- Other Nosocomial Pneumonia
Blood Stream Infection
Other Infection

By Route of Administration

Oral
Intravenous
Other Routes

By Geography

North America
- Canada
- U.S.
- Mexico
Europe
- Germany
- France
- Spain
- Italy
- UK
- Rest of Europe
Asia-Pacific
- Japan
- India
- China
- South Korea
- Indonesia
- Thailand
- Vietnam
- Taiwan
- Rest of Asia-Pacific
RoW
- Saudi Arabia
- Brazil
- Remaining Countries

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Analysis Period	2019–2030
Base Year Considered	2020
Forecast Period	2020–2030
Market Size Estimation	Billion (USD)
Market Segmentation	By Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, Combination) By Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection, Complicated Intra-Abdominal Infections, Nosocomial Pneumonia, Blood Stream Infection, Other Diseases) By Route of Administration (Oral, Intravenous, Other Route of Administration)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (Germany, UK, Spain, France, Italy, Rest of Europe), Asia-Pacific (Indonesia, China, India, Japan, South Korea, Thailand, Vietnam, Taiwan, Rest of APAC) Rest of World (Brazil, Saudi Arabia, Remaining Countries)
Companies Profiled	Allergan Plc., Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Mylan N.V., Merck & Co. Inc., Pfizer Inc., Novartis International AG (Sandoz), Teva Pharmaceutical Industries Ltd., Sanofi.

KEY PLAYERS:

Allergan Plc.
Abbott Laboratories
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Merck & Co. Inc.
Pfizer Inc.
Novartis International AG (Sandoz)
Teva Pharmaceutical Industries Ltd.
Sanofi

1. INTRODUCTION

1.1. REPORT DESCRIPTION

1.2. RESEARCH METHODOLOGY

1.2.1 SECONDARY RESEARCH

1.2.2 DATA ANALYSIS FRAMEWORK

1.2.3 MARKET SIZE ESTIMATION

1.2.4 FORECASTING

1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

2. MARKET SNAPSHOT, 2021-2030 MILLION USD

2.1. MARKET SNAPSHOT

3. PORTER’S FIVE FORCE MODEL ANALYSIS

4. MARKET DYNAMICS

4.1. GROWTH DRIVERS

4.1.1 DRIVER 1

4.1.2 DRIVER 2

4.1.3 DRIVER 3

4.1.4 DRIVER 4

4.2. CHALLENGES

4.2.1 CHALLENGE 1

4.2.2 CHALLENGE 2

4.3. OPPORTUNITIES

4.3.1 OPPORTUNITY 1

4.3.2 OPPORTUNITY 2

5. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

5.1. OVERVIEW

5.2. PENICILLIN

5.2.1 PENICILLIN MARKET, BY REGION

5.2.1.1 NORTH AMERICA PENICILLIN MARKET, BY COUNTRY

5.2.1.2 EUROPE PENICILLIN MARKET, BY COUNTRY

5.2.1.3 ASIA-PACIFIC PENICILLIN MARKET, BY COUNTRY

5.2.1.4 REST OF WORLD PENICILLIN MARKET, BY COUNTRY

5.3. CEPHALOSPORIN

5.3.1 CEPHALOSPORIN MARKET, BY REGION

5.3.1.1 NORTH AMERICA CEPHALOSPORIN MARKET, BY COUNTRY

5.3.1.2 EUROPE CEPHALOSPORIN MARKET, BY COUNTRY

5.3.1.3 ASIA-PACIFIC CEPHALOSPORIN MARKET, BY COUNTRY

5.3.1.4 REST OF WORLD CEPHALOSPORIN MARKET, BY COUNTRY

5.4. CARBAPENEM

5.4.1 CARBAPENEM MARKET, BY REGION

5.4.1.1 NORTH AMERICA CARBAPENEM MARKET, BY COUNTRY

5.4.1.2 EUROPE CARBAPENEM MARKET, BY COUNTRY

5.4.1.3 ASIA-PACIFIC CARBAPENEM MARKET, BY COUNTRY

5.4.1.4 REST OF WORLD CARBAPENEM MARKET, BY COUNTRY

5.5. MONOBACTAM

5.5.1 MONOBACTAM MARKET, BY REGION

5.5.1.1 NORTH AMERICA MONOBACTAM MARKET, BY COUNTRY

5.5.1.2 EUROPE MONOBACTAM MARKET, BY COUNTRY

5.5.1.3 ASIA-PACIFIC MONOBACTAM MARKET, BY COUNTRY

5.5.1.4 REST OF WORLD MONOBACTAM MARKET, BY COUNTRY

5.6. COMBINATION

5.6.1 GLOBAL COMBINATION MARKET, BY DRUG CLASS

5.6.1.1 PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY REGION

5.6.1.1.1 NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.1.2 EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.1.3 ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.1.4 REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.2 CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY REGION

5.6.1.2.1 NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.2.2 EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.2.3 ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.2.4 REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.3 CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY REGION

5.6.1.3.1 NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.3.2 EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.3.3 ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.3.4 REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.2 COMBINATION MARKET, BY REGION

5.6.2.1 NORTH AMERICA COMBINATION MARKET, BY COUNTRY

5.6.2.2 EUROPE COMBINATION MARKET, BY COUNTRY

5.6.2.3 ASIA-PACIFIC COMBINATION MARKET, BY COUNTRY

5.6.2.4 REST OF WORLD COMBINATION MARKET, BY COUNTRY

6. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

6.1. OVERVIEW

6.2. URINARY TRACT INFECTION

6.2.1 URINARY TRACT INFECTION MARKET, BY REGION

6.2.1.1 NORTH AMERICA URINARY TRACT INFECTION MARKET, BY COUNTRY

6.2.1.2 EUROPE URINARY TRACT INFECTION MARKET, BY COUNTRY

6.2.1.3 ASIA-PACIFIC URINARY TRACT INFECTION MARKET, BY COUNTRY

6.2.1.4 REST OF WORLD URINARY TRACT INFECTION MARKET, BY COUNTRY

6.3. RESPIRATORY INFECTION

6.3.1 RESPIRATORY INFECTION MARKET, BY REGION

6.3.1.1 NORTH AMERICA RESPIRATORY INFECTION MARKET, BY COUNTRY

6.3.1.2 EUROPE RESPIRATORY INFECTION MARKET, BY COUNTRY

6.3.1.3 ASIA-PACIFIC RESPIRATORY INFECTION MARKET, BY COUNTRY

6.3.1.4 REST OF WORLD RESPIRATORY INFECTION MARKET, BY COUNTRY

6.4. SKIN INFECTION

6.4.1 SKIN INFECTION MARKET, BY REGION

6.4.1.1 NORTH AMERICA SKIN INFECTION MARKET, BY COUNTRY

6.4.1.2 EUROPE SKIN INFECTION MARKET, BY COUNTRY

6.4.1.3 ASIA-PACIFIC SKIN INFECTION MARKET, BY COUNTRY

6.4.1.4 REST OF WORLD SKIN INFECTION MARKET, BY COUNTRY

6.5. COMPLICATED URINARY TRACT INFECTION

6.5.1 COMPLICATED URINARY TRACT INFECTION MARKET, BY REGION

6.5.1.1 NORTH AMERICA COMPLICATED URINARY TRACT INFECTION MARKET, BY COUNTRY

6.5.1.2 EUROPE COMPLICATED URINARY TRACT INFECTION MARKET, BY COUNTRY

6.5.1.3 ASIA-PACIFIC COMPLICATED URINARY TRACT INFECTION MARKET, BY COUNTRY

6.5.1.4 REST OF WORLD COMPLICATED URINARY TRACT INFECTION MARKET, BY COUNTRY

6.6. COMPLICATED INTRA-ABDOMINAL INFECTIONS

6.6.1 COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY REGION

6.6.1.1 NORTH AMERICA COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY COUNTRY

6.6.1.2 EUROPE COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY COUNTRY

6.6.1.3 ASIA-PACIFIC COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY COUNTRY

6.6.1.4 REST OF WORLD COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY COUNTRY

6.7. NOSOCOMIAL PNEUMONIA

6.7.1 GLOBAL NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

6.7.1.1 HOSPITAL ACQUIRED PNEUMONIA MARKET, BY REGION

6.7.1.1.1 NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY

6.7.1.1.2 EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY

6.7.1.1.3 ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY

6.7.1.1.4 REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY

6.7.1.2 VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY REGION

6.7.1.2.1 NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY

6.7.1.2.2 EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY

6.7.1.2.3 ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY

6.7.1.2.4 REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY

6.7.1.3 OTHER NOSOCOMIAL PNEUMONIA MARKET, BY REGION

6.7.1.3.1 NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.1.3.2 EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.1.3.3 ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.1.3.4 REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.2 NOSOCOMIAL PNEUMONIA MARKET, BY REGION

6.7.2.1 NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.2.2 EUROPE NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.2.3 ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.2.4 REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.8. BLOOD STREAM INFECTION

6.8.1 BLOOD STREAM INFECTION MARKET, BY REGION

6.8.1.1 NORTH AMERICA BLOOD STREAM INFECTION MARKET, BY COUNTRY

6.8.1.2 EUROPE BLOOD STREAM INFECTION MARKET, BY COUNTRY

6.8.1.3 ASIA-PACIFIC BLOOD STREAM INFECTION MARKET, BY COUNTRY

6.8.1.4 REST OF WORLD BLOOD STREAM INFECTION MARKET, BY COUNTRY

6.9. OTHER DISEASES

6.9.1 OTHER DISEASES MARKET, BY REGION

6.9.1.1 NORTH AMERICA OTHER DISEASES MARKET, BY COUNTRY

6.9.1.2 EUROPE OTHER DISEASES MARKET, BY COUNTRY

6.9.1.3 ASIA-PACIFIC OTHER DISEASES MARKET, BY COUNTRY

6.9.1.4 REST OF WORLD OTHER DISEASES MARKET, BY COUNTRY

7. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

7.1. OVERVIEW

7.2. ORAL

7.2.1 ORAL MARKET, BY REGION

7.2.1.1 NORTH AMERICA ORAL MARKET, BY COUNTRY

7.2.1.2 EUROPE ORAL MARKET, BY COUNTRY

7.2.1.3 ASIA-PACIFIC ORAL MARKET, BY COUNTRY

7.2.1.4 REST OF WORLD ORAL MARKET, BY COUNTRY

7.3. INTRAVENOUS

7.3.1 INTRAVENOUS MARKET, BY REGION

7.3.1.1 NORTH AMERICA INTRAVENOUS MARKET, BY COUNTRY

7.3.1.2 EUROPE INTRAVENOUS MARKET, BY COUNTRY

7.3.1.3 ASIA-PACIFIC INTRAVENOUS MARKET, BY COUNTRY

7.3.1.4 REST OF WORLD INTRAVENOUS MARKET, BY COUNTRY

7.4. OTHER ROUTE OF ADMINISTRATION

7.4.1 OTHER ROUTE OF ADMINISTRATION MARKET, BY REGION

7.4.1.1 NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET, BY COUNTRY

7.4.1.2 EUROPE OTHER ROUTE OF ADMINISTRATION MARKET, BY COUNTRY

7.4.1.3 ASIA-PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET, BY COUNTRY

7.4.1.4 REST OF WORLD OTHER ROUTE OF ADMINISTRATION MARKET, BY COUNTRY

8. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY REGION

8.1. OVERVIEW

8.2. NORTH AMERICA

8.2.1 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.2.1.1 NORTH AMERICA COMBINATION MARKET, BY DRUG CLASS

8.2.2 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.2.2.1 NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.2.3 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.2.4 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS, MARKET BY COUNTRY

8.2.4.1 U.S.

8.2.4.1.1 U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.2.4.1.1.1. U.S. COMBINATION MARKET, BY DRUG CLASS

8.2.4.1.2 U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.2.4.1.2.1. U.S. NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.2.4.1.3 U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.2.4.2 CANADA

8.2.4.2.1 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.2.4.2.1.1. CANADA COMBINATION MARKET, BY DRUG CLASS

8.2.4.2.2 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.2.4.2.2.1. CANADA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.2.4.2.3 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.2.4.3 MEXICO

8.2.4.3.1 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.2.4.3.1.1. MEXICO COMBINATION MARKET, BY DRUG CLASS

8.2.4.3.2 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.2.4.3.2.1. MEXICO NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.2.4.3.3 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.3. EUROPE

8.3.1 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.3.1.1 EUROPE COMBINATION MARKET, BY DRUG CLASS

8.3.2 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.3.2.1 EUROPE NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.3.3 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.3.4 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS, MARKET BY COUNTRY

8.3.4.1 GERMANY

8.3.4.1.1 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.3.4.1.1.1. GERMANY COMBINATION MARKET, BY DRUG CLASS

8.3.4.1.2 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.3.4.1.2.1. GERMANY NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.3.4.1.3 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.3.4.2 UK

8.3.4.2.1 UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.3.4.2.1.1. UK COMBINATION MARKET, BY DRUG CLASS

8.3.4.2.2 UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.3.4.2.2.1. UK NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.3.4.2.3 UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.3.4.3 FRANCE

8.3.4.3.1 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.3.4.3.1.1. FRANCE COMBINATION MARKET, BY DRUG CLASS

8.3.4.3.2 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.3.4.3.2.1. FRANCE NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.3.4.3.3 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.3.4.4 SPAIN

8.3.4.4.1 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.3.4.4.1.1. SPAIN COMBINATION MARKET, BY DRUG CLASS

8.3.4.4.2 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.3.4.4.2.1. SPAIN NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.3.4.4.3 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.3.4.5 ITALY

8.3.4.5.1 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.3.4.5.1.1. ITALY COMBINATION MARKET, BY DRUG CLASS

8.3.4.5.2 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.3.4.5.2.1. ITALY NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.3.4.5.3 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.3.4.6 REST OF EUROPE

8.3.4.6.1 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.3.4.6.1.1. REST OF EUROPE COMBINATION MARKET, BY DRUG CLASS

8.3.4.6.2 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.3.4.6.2.1. REST OF EUROPE NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.3.4.6.3 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4. ASIA-PACIFIC

8.4.1 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.1.1 ASIA-PACIFIC COMBINATION MARKET, BY DRUG CLASS

8.4.2 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.2.1 ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.3 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS, MARKET BY COUNTRY

8.4.4.1 JAPAN

8.4.4.1.1 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.1.1.1. JAPAN COMBINATION MARKET, BY DRUG CLASS

8.4.4.1.2 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.1.2.1. JAPAN NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.1.3 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4.2 INDIA

8.4.4.2.1 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.2.1.1. INDIA COMBINATION MARKET, BY DRUG CLASS

8.4.4.2.2 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.2.2.1. INDIA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.2.3 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4.3 CHINA

8.4.4.3.1 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.3.1.1. CHINA COMBINATION MARKET, BY DRUG CLASS

8.4.4.3.2 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.3.2.1. CHINA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.3.3 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4.4 SOUTH KOREA

8.4.4.4.1 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.4.1.1. SOUTH KOREA COMBINATION MARKET, BY DRUG CLASS

8.4.4.4.2 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.4.2.1. SOUTH KOREA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.4.3 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4.5 INDONESIA

8.4.4.5.1 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.5.1.1. INDONESIA COMBINATION MARKET, BY DRUG CLASS

8.4.4.5.2 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.5.2.1. INDONESIA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.5.3 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4.6 THAILAND

8.4.4.6.1 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.6.1.1. THAILAND COMBINATION MARKET, BY DRUG CLASS

8.4.4.6.2 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.6.2.1. THAILAND NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.6.3 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4.7 VIETNAM

8.4.4.7.1 VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.7.1.1. VIETNAM COMBINATION MARKET, BY DRUG CLASS

8.4.4.7.2 VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.7.2.1. VIETNAM NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.7.3 VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4.8 TAIWAN

8.4.4.8.1 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.8.1.1. TAIWAN COMBINATION MARKET, BY DRUG CLASS

8.4.4.8.2 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.8.2.1. TAIWAN NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.8.3 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.4.4.9 REST OF ASIA-PACIFIC

8.4.4.9.1 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.4.4.9.1.1. REST OF ASIA-PACIFIC COMBINATION MARKET, BY DRUG CLASS

8.4.4.9.2 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.4.4.9.2.1. REST OF ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.4.4.9.3 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.5. REST OF WORLD

8.5.1 REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.5.1.1 REST OF WORLD COMBINATION MARKET, BY DRUG CLASS

8.5.2 REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.5.2.1 REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.5.3 REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.5.4 REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS, MARKET BY COUNTRY

8.5.4.1 BRAZIL

8.5.4.1.1 BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.5.4.1.1.1. BRAZIL COMBINATION MARKET, BY DRUG CLASS

8.5.4.1.2 BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.5.4.1.2.1. BRAZIL NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.5.4.1.3 BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.5.4.2 SAUDI ARABIA

8.5.4.2.1 SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.5.4.2.1.1. SAUDI ARABIA COMBINATION MARKET, BY DRUG CLASS

8.5.4.2.2 SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.5.4.2.2.1. SAUDI ARABIA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.5.4.2.3 SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

8.5.4.3 REMAINING COUNTRIES

8.5.4.3.1 REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS

8.5.4.3.1.1. REMAINING COUNTRIES COMBINATION MARKET, BY DRUG CLASS

8.5.4.3.2 REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE

8.5.4.3.2.1. REMAINING COUNTRIES NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE

8.5.4.3.3 REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

9. COMPANY PROFILES

9.1. ABBOTT LABORATORIES

9.1.1 COMPANY OVERVIEW

9.1.2 COMPANY SNAPSHOT

9.1.3 OPERATING BUSINESS SEGMENTS

9.1.4 PRODUCT PORTFOLIO

9.1.5 BUSINESS PERFORMANCE

9.1.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.2. ALLERGAN PLC.

9.2.1 COMPANY OVERVIEW

9.2.2 COMPANY SNAPSHOT

9.2.3 OPERATING BUSINESS SEGMENTS

9.2.4 PRODUCT PORTFOLIO

9.2.5 BUSINESS PERFORMANCE

9.2.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.3. F. HOFFMANN-LA ROCHE LTD.

9.3.1 COMPANY OVERVIEW

9.3.2 COMPANY SNAPSHOT

9.3.3 OPERATING BUSINESS SEGMENTS

9.3.4 PRODUCT PORTFOLIO

9.3.5 BUSINESS PERFORMANCE

9.3.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.4. GLAXOSMITHKLINE PLC

9.4.1 COMPANY OVERVIEW

9.4.2 COMPANY SNAPSHOT

9.4.3 OPERATING BUSINESS SEGMENTS

9.4.4 PRODUCT PORTFOLIO

9.4.5 BUSINESS PERFORMANCE

9.4.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.5. MERCK & CO. INC.

9.5.1 COMPANY OVERVIEW

9.5.2 COMPANY SNAPSHOT

9.5.3 OPERATING BUSINESS SEGMENTS

9.5.4 PRODUCT PORTFOLIO

9.5.5 BUSINESS PERFORMANCE

9.5.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.6. MYLAN N.V.

9.6.1 COMPANY OVERVIEW

9.6.2 COMPANY SNAPSHOT

9.6.3 OPERATING BUSINESS SEGMENTS

9.6.4 PRODUCT PORTFOLIO

9.6.5 BUSINESS PERFORMANCE

9.6.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.7. NOVARTIS INTERNATIONAL AG

9.7.1 COMPANY OVERVIEW

9.7.2 COMPANY SNAPSHOT

9.7.3 OPERATING BUSINESS SEGMENTS

9.7.4 PRODUCT PORTFOLIO

9.7.5 BUSINESS PERFORMANCE

9.7.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.8. PFIZER INC.

9.8.1 COMPANY OVERVIEW

9.8.2 COMPANY SNAPSHOT

9.8.3 OPERATING BUSINESS SEGMENTS

9.8.4 PRODUCT PORTFOLIO

9.8.5 BUSINESS PERFORMANCE

9.8.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.9. SANOFI

9.9.1 COMPANY OVERVIEW

9.9.2 COMPANY SNAPSHOT

9.9.3 OPERATING BUSINESS SEGMENTS

9.9.4 PRODUCT PORTFOLIO

9.9.5 BUSINESS PERFORMANCE

9.9.6 KEY STRATEGIC MOVES AND DEVELOPMENT

9.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

9.10.1 COMPANY OVERVIEW

9.10.2 COMPANY SNAPSHOT

9.10.3 OPERATING BUSINESS SEGMENTS

9.10.4 PRODUCT PORTFOLIO

9.10.5 BUSINESS PERFORMANCE

9.10.6 KEY STRATEGIC MOVES AND DEVELOPMENT

LIST OF TABLES

TABLE 1. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 2. PENICILLIN MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 3. NORTH AMERICA PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 4. EUROPE PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 5. ASIA-PACIFIC PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 6. REST OF WORLD PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 7. CEPHALOSPORIN MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 8. NORTH AMERICA CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 9. EUROPE CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 10. ASIA-PACIFIC CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 11. REST OF WORLD CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 12. CARBAPENEM MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 13. NORTH AMERICA CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 14. EUROPE CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 15. ASIA-PACIFIC CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 16. REST OF WORLD CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 17. MONOBACTAM MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 18. NORTH AMERICA MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 19. EUROPE MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 20. ASIA-PACIFIC MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 21. REST OF WORLD MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 22. GLOBAL COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 23. PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 24. NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 25. EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 26. ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 27. REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 28. CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 29. NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 30. EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 31. ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 32. REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 33. CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 34. NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 35. EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 36. ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 37. REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 38. COMBINATION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 39. NORTH AMERICA COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 40. EUROPE COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 41. ASIA-PACIFIC COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 42. REST OF WORLD COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 43. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 44. URINARY TRACT INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 45. NORTH AMERICA URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 46. EUROPE URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 47. ASIA-PACIFIC URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 48. REST OF WORLD URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 49. RESPIRATORY INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 50. NORTH AMERICA RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 51. EUROPE RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 52. ASIA-PACIFIC RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 53. REST OF WORLD RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 54. SKIN INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 55. NORTH AMERICA SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 56. EUROPE SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 57. ASIA-PACIFIC SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 58. REST OF WORLD SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 59. COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 60. NORTH AMERICA COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 61. EUROPE COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 62. ASIA-PACIFIC COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 63. REST OF WORLD COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 64. COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 65. NORTH AMERICA COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 66. EUROPE COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 67. ASIA-PACIFIC COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 68. REST OF WORLD COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 69. GLOBAL NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 70. HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 71. NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 72. EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 73. ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 74. REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 75. VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 76. NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 77. EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 78. ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 79. REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 80. OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 81. NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 82. EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 83. ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 84. REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 85. NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 86. NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 87. EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 88. ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 89. REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 90. BLOOD STREAM INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 91. NORTH AMERICA BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 92. EUROPE BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 93. ASIA-PACIFIC BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 94. REST OF WORLD BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 95. OTHER DISEASES MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 96. NORTH AMERICA OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 97. EUROPE OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 98. ASIA-PACIFIC OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 99. REST OF WORLD OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 100. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 101. ORAL MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 102. NORTH AMERICA ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 103. EUROPE ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 104. ASIA-PACIFIC ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 105. REST OF WORLD ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 106. INTRAVENOUS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 107. NORTH AMERICA INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 108. EUROPE INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 109. ASIA-PACIFIC INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 110. REST OF WORLD INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 111. OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 112. NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 113. EUROPE OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 114. ASIA-PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 115. REST OF WORLD OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

TABLE 116. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

TABLE 117. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 118. NORTH AMERICA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 119. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 120. NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 121. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 122. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 123. U.S. COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 124. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 125. U.S. NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 126. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 127. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 128. CANADA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 129. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 130. CANADA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 131. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 132. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 133. MEXICO COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 134. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 135. MEXICO NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 136. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 137. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 138. EUROPE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 139. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 140. EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 141. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 142. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 143. GERMANY COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 144. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 145. GERMANY NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 146. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 147. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 148. UK COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 149. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 150. UK NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 151. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 152. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 153. FRANCE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 154. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 155. FRANCE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 156. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 157. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 158. SPAIN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 159. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 160. SPAIN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 161. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 162. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 163. ITALY COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 164. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 165. ITALY NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 166. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 167. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 168. REST OF EUROPE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 169. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 170. REST OF EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 171. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 172. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 173. ASIA-PACIFIC COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 174. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 175. ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 176. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 177. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 178. JAPAN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 179. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 180. JAPAN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 181. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 182. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 183. INDIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 184. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 185. INDIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 186. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 187. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 188. CHINA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 189. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 190. CHINA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 191. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 192. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 193. SOUTH KOREA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 194. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 195. SOUTH KOREA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 196. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 197. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 198. INDONESIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 199. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 200. INDONESIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 201. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 202. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 203. THAILAND COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 204. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 205. THAILAND NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 206. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 207. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 208. VIETNAM COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 209. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 210. VIETNAM NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 211. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 212. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 213. TAIWAN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 214. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 215. TAIWAN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 216. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 217. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 218. REST OF ASIA-PACIFIC COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 219. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 220. REST OF ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 221. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 222. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 223. REST OF WORLD COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 224. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 225. REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 226. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 227. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 228. BRAZIL COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 229. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 230. BRAZIL NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 231. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 232. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 233. SAUDI ARABIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 234. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 235. SAUDI ARABIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 236. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 237. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 238. REMAINING COUNTRIES COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

TABLE 239. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 240. REMAINING COUNTRIES NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

TABLE 241. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

TABLE 242. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 243. ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 244. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 245. ABBOTT LABORATORIES: KEY STRATERGY

TABLE 246. ALLERGAN PLC.: COMPANY SNAPSHOT

TABLE 247. ALLERGAN PLC.: OPERATING SEGMENTS

TABLE 248. ALLERGAN PLC.: PRODUCT PORTFOLIO

TABLE 249. ALLERGAN PLC.: KEY STRATERGY

TABLE 250. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 251. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS

TABLE 252. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 253. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGY

TABLE 254. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 255. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS

TABLE 256. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 257. GLAXOSMITHKLINE PLC: KEY STRATERGY

TABLE 258. MERCK & CO. INC.: COMPANY SNAPSHOT

TABLE 259. MERCK & CO. INC.: OPERATING SEGMENTS

TABLE 260. MERCK & CO. INC.: PRODUCT PORTFOLIO

TABLE 261. MERCK & CO. INC.: KEY STRATERGY

TABLE 262. MYLAN N.V.: COMPANY SNAPSHOT

TABLE 263. MYLAN N.V.: OPERATING SEGMENTS

TABLE 264. MYLAN N.V.: PRODUCT PORTFOLIO

TABLE 265. MYLAN N.V.: KEY STRATERGY

TABLE 266. NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT

TABLE 267. NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS

TABLE 268. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO

TABLE 269. NOVARTIS INTERNATIONAL AG: KEY STRATERGY

TABLE 270. PFIZER INC.: COMPANY SNAPSHOT

TABLE 271. PFIZER INC.: OPERATING SEGMENTS

TABLE 272. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 273. PFIZER INC.: KEY STRATERGY

TABLE 274. SANOFI: COMPANY SNAPSHOT

TABLE 275. SANOFI: OPERATING SEGMENTS

TABLE 276. SANOFI: PRODUCT PORTFOLIO

TABLE 277. SANOFI: KEY STRATERGY

TABLE 278. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 279. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS

TABLE 280. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 281. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 2. PENICILLIN MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 3. NORTH AMERICA PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 4. EUROPE PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 5. ASIA-PACIFIC PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 6. REST OF WORLD PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 7. CEPHALOSPORIN MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 8. NORTH AMERICA CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 9. EUROPE CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 10. ASIA-PACIFIC CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 11. REST OF WORLD CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 12. CARBAPENEM MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 13. NORTH AMERICA CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 14. EUROPE CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 15. ASIA-PACIFIC CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 16. REST OF WORLD CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 17. MONOBACTAM MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 18. NORTH AMERICA MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 19. EUROPE MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 20. ASIA-PACIFIC MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 21. REST OF WORLD MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 22. GLOBAL COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 23. PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 24. NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 25. EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 26. ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 27. REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 28. CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 29. NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 30. EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 31. ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 32. REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 33. CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 34. NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 35. EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 36. ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 37. REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 38. COMBINATION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 39. NORTH AMERICA COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 40. EUROPE COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 41. ASIA-PACIFIC COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 42. REST OF WORLD COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 43. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 44. URINARY TRACT INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 45. NORTH AMERICA URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 46. EUROPE URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 47. ASIA-PACIFIC URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 48. REST OF WORLD URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 49. RESPIRATORY INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 50. NORTH AMERICA RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 51. EUROPE RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 52. ASIA-PACIFIC RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 53. REST OF WORLD RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 54. SKIN INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 55. NORTH AMERICA SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 56. EUROPE SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 57. ASIA-PACIFIC SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 58. REST OF WORLD SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 59. COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 60. NORTH AMERICA COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 61. EUROPE COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 62. ASIA-PACIFIC COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 63. REST OF WORLD COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 64. COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 65. NORTH AMERICA COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 66. EUROPE COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 67. ASIA-PACIFIC COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 68. REST OF WORLD COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 69. GLOBAL NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 70. HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 71. NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 72. EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 73. ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 74. REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 75. VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 76. NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 77. EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 78. ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 79. REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 80. OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 81. NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 82. EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 83. ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 84. REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 85. NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 86. NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 87. EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 88. ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 89. REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 90. BLOOD STREAM INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 91. NORTH AMERICA BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 92. EUROPE BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 93. ASIA-PACIFIC BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 94. REST OF WORLD BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 95. OTHER DISEASES MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 96. NORTH AMERICA OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 97. EUROPE OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 98. ASIA-PACIFIC OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 99. REST OF WORLD OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 100. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 101. ORAL MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 102. NORTH AMERICA ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 103. EUROPE ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 104. ASIA-PACIFIC ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 105. REST OF WORLD ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 106. INTRAVENOUS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 107. NORTH AMERICA INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 108. EUROPE INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 109. ASIA-PACIFIC INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 110. REST OF WORLD INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 111. OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 112. NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 113. EUROPE OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 114. ASIA-PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 115. REST OF WORLD OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD

FIGURE 116. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD

FIGURE 117. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 118. NORTH AMERICA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 119. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 120. NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 121. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 122. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 123. U.S. COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 124. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 125. U.S. NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 126. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 127. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 128. CANADA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 129. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 130. CANADA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 131. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 132. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 133. MEXICO COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 134. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 135. MEXICO NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 136. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 137. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 138. EUROPE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 139. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 140. EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 141. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 142. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 143. GERMANY COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 144. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 145. GERMANY NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 146. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 147. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 148. UK COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 149. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 150. UK NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 151. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 152. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 153. FRANCE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 154. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 155. FRANCE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 156. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 157. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 158. SPAIN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 159. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 160. SPAIN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 161. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 162. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 163. ITALY COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 164. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 165. ITALY NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 166. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 167. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 168. REST OF EUROPE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 169. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 170. REST OF EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 171. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 172. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 173. ASIA-PACIFIC COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 174. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 175. ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 176. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 177. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 178. JAPAN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 179. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 180. JAPAN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 181. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 182. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 183. INDIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 184. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 185. INDIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 186. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 187. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 188. CHINA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 189. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 190. CHINA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 191. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 192. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 193. SOUTH KOREA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 194. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 195. SOUTH KOREA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 196. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 197. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 198. INDONESIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 199. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 200. INDONESIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 201. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 202. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 203. THAILAND COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 204. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 205. THAILAND NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 206. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 207. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 208. VIETNAM COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 209. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 210. VIETNAM NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 211. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 212. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 213. TAIWAN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 214. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 215. TAIWAN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 216. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 217. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 218. REST OF ASIA-PACIFIC COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 219. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 220. REST OF ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 221. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 222. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 223. REST OF WORLD COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 224. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 225. REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 226. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 227. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 228. BRAZIL COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 229. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 230. BRAZIL NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 231. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 232. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 233. SAUDI ARABIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 234. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 235. SAUDI ARABIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 236. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 237. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 238. REMAINING COUNTRIES COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD

FIGURE 239. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 240. REMAINING COUNTRIES NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD

FIGURE 241. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD

FIGURE 242. ABBOTT LABORATORIES: NET SALES,2017-2019

FIGURE 243. ALLERGAN PLC.: NET SALES,2017-2019

FIGURE 244. F. HOFFMANN-LA ROCHE LTD.: NET SALES,2017-2019

FIGURE 245. GLAXOSMITHKLINE PLC: NET SALES,2017-2019

FIGURE 246. MERCK & CO. INC.: NET SALES,2017-2019

FIGURE 247. MYLAN N.V.: NET SALES,2017-2019

FIGURE 248. NOVARTIS INTERNATIONAL AG: NET SALES,2017-2019

FIGURE 249. PFIZER INC.: NET SALES,2017-2019

FIGURE 250. SANOFI: NET SALES,2017-2019

FIGURE 251. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,2017-2019

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

According to the report published by Next Move Strategy Consulting, the Beta-lactam and Beta-lactamase Inhibitors market business is expected to hit at $34.20 billion (USD) by 2030.

North America is expected to hold the highest market share in the global market. The region is expected to witness remarkable growth as it houses the major key players in the market.

Abbott Laboratories, Allergan plc. F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck & Co. Inc. Mylan N.V., Novartis International AG, Pfizer Inc.

The global Beta-lactam and Beta-lactamase Inhibitors market share analysis is based on drug class, disease, route of administration and geography.

Currently (in 2019), the market value stands at USD 27.49 billion and it is anticipated to reach USD 34.20 billion by 2030.

Download Free Sample

Phone Number *

Please enter Country Code and Phone No

Yes, I have read the Privacy Policy

Multi User

$4,975

Single User

$3,975

Enterprise

$6,975

Datapack

$2,975

Speak to Our Analyst

Our Clients

View All

Features
	Single User	Multi User	Enterprise User	Data Pack
	US $ 3,975	US $ 4,975	US $ 6,975	US $ 2,975
	1 user only	1 user only	Unlimited access within the Organization	1 user only

Free Customization	20 hours	40 hours	>60 hours	NA
Duration Of Free Analyst Support	3 months post purchase	6 months post purchase	12 months post purchase	NA
Direct Access to the Analyst Team Through Calls / Email
Deliverable Format
Deliverable Format
Discount on Your Next Purchase	No Discount	15%	No Discount	No Discount
Permission to Print the Report

Trending Report

Beta-lactam and Beta-lactamase Inhibitors Market

Market Definition:

Market Dynamics and Trends:

Market Segmentations and Scope of the Study:

Geographical Analysis:

Competitive Landscape:

KEY BENEFITS:

KEY MARKET SEGMENTS:

By Drug Class

By Disease

By Route of Administration

By Geography

KEY PLAYERS:

Qualitative Approach

Our Specialized Toolbox for Industry-Specific Market Research

Information Procurement

Market Research Approach

Porters Five Forces Analysis

SWOT Analysis

Forecasting

Frequently Asked Questions

Download Free Sample

Our Clients

Features

Follow Us On

We Accept

Industries

Trending Report

Beta-lactam and Beta-lactamase Inhibitors Market

Market Definition:

Market Dynamics and Trends:

Market Segmentations and Scope of the Study:

Geographical Analysis:

Competitive Landscape:

KEY BENEFITS:

KEY MARKET SEGMENTS:

By Drug Class

By Disease

By Route of Administration

By Geography

KEY PLAYERS:

Qualitative Approach

Our Specialized Toolbox for Industry-Specific Market Research

Information Procurement

Market Research Approach

Porters Five Forces Analysis

SWOT Analysis

Forecasting

Frequently Asked Questions

What will be the worth of global Beta-lactam and Beta-lactamase Inhibitors market by the end of 2030?

Which region is expected to hold the highest market share in the Beta-lactam and Beta-lactamase Inhibitors market?

Which are the top companies in the Beta-lactam and Beta-lactamase Inhibitors industry?

What are the market segmentations and scope of the study?

How big is the Beta-lactam and Beta-lactamase Inhibitors market?

Download Free Sample

Our Clients

Related Report

Related Blogs

The Future of Immunoassays in Latin America: Trends and Predictions

Future Trends in Pharmaceutical Isolators: Enhancing Safety and Efficiency

Early Toxicity Testing: Essential Essence of Drug Development